Sonoma Pharmaceuticals, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K, dated August 8, 2018, reports the issuance of a press release regarding financial results for the fiscal quarter ended June 30, 2018. The registrant is Sonoma Pharmaceuticals, Inc., a Delaware corporation headquartered in Petaluma, California.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These details are contained within the press release (Exhibit 99.1) and presentation (Exhibit 99.2), which are furnished but not deemed "filed" for liability purposes under Section 18 of the Securities Exchange Act of 1934.
Material Changes
The filing does not explicitly detail material changes versus the prior comparable period within the body text. Investors must refer to the attached exhibits for comparative financial data.
Guidance, Outlook, and Risks
The report contains forward-looking statements regarding the Company's intentions, beliefs, expectations, and strategies. Management notes that these statements are based on current assumptions and are not guarantees of future performance. Actual results may differ materially due to risks and uncertainties discussed in the Company's Annual Report on Form 10-K and other SEC filings. The Company does not undertake an obligation to update these statements except as required by law.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q2 2018 revenue, net income, and cash position figures.
- Examine Exhibit 99.2 (Presentation) for management's outlook and strategic updates.
- Consult the most recent Form 10-K for a comprehensive list of risk factors affecting forward-looking statements.
- Verify the status of any clinical trials or regulatory approvals mentioned in the exhibits, as these are critical for a pharmaceutical company's valuation.